1. Home
  2. ARMP vs NERV Comparison

ARMP vs NERV Comparison

Compare ARMP & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

N/A

Current Price

$3.72

Market Cap

199.7M

Sector

Health Care

ML Signal

N/A

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

N/A

Current Price

$2.33

Market Cap

166.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ARMP
NERV
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.7M
166.4M
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
ARMP
NERV
Price
$3.72
$2.33
Analyst Decision
Strong Buy
Buy
Analyst Count
2
3
Target Price
★ $17.50
$10.33
AVG Volume (30 Days)
75.1K
★ 179.3K
Earning Date
11-12-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $41,175,600.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.75
$1.96
52 Week High
$14.98
$8.80

Technical Indicators

Market Signals
Indicator
ARMP
NERV
Relative Strength Index (RSI) 55.78 39.95
Support Level $3.38 $1.96
Resistance Level $3.96 $2.65
Average True Range (ATR) 0.36 0.24
MACD 0.11 0.06
Stochastic Oscillator 93.64 42.50

Price Performance

Historical Comparison
ARMP
NERV

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: